Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Meditation or health classes may ease burden of vision loss

NCT ID NCT03166072

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether meditation or a health education program can improve quality of life and mental health for people with irreversible age-related vision loss and their caregivers. About 150 participants will be assigned to either meditation training or health classes, both delivered online. The main goal is to see if these programs are practical and helpful, not to cure vision loss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Meditation and Health Enhancement Program (behavioral interventions)
What this could lead to
If successful, this could show that meditation or health education programs help people with vision loss and their caregivers feel better emotionally and improve daily life.
What could go wrong
This is a small, early feasibility study, not a large trial. It may not prove that these programs work for everyone, and results may not apply to all types of vision loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with irreversible age-related vision loss (IARVL) and have ongoing significant disability and/or their caregivers who agree to consent. * IARVL patients between age 60 to 85 years or caregivers between 18 to 85 years. * Deemed competent to provide individual consent to participate. * Speak and understand English without requirement for interpretation or assistance. * Have no significant self-reported or physician diagnosed mental health disorder other than depressive and/or anxiety symptoms. * Have either a minimum of CES-D 20-item scale score of 16 OR a minimum of 8 on the Hospital Anxiety Scale (HADS-A) 7-item sub-scale. * Have sufficient hearing to be able to follow verbal instructions * Ability to sit independently without physical discomfort for 30 minutes. * Willing and able to attend, via Microsoft TEAMS software, the four initial training sessions of MEDITATION or HEP and at least 6 follow-up sessions. * Willing to dedicate 33 minutes per day to their assigned home practice. Exclusion Criteria: * Inability to provide informed consent. * Dementia as defined by MoCA \< 21. * Have significant suicidal ideation as per self-report (CES-D = 3 on item question 14 and/or 15). * Have severe depression CES-D ≥ 24. * Participating in other similar studies. * Have a lifetime diagnosis of self-reported other mental disorders, including bipolar I or II disorder, primary psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder). * Self-reported substance abuse or dependence within the past 3 months. * Have an acutely unstable medical illnesses, including delirium or acute cerebrovascular or cardiovascular events within the last 6 months. * Have a terminal medical diagnosis with prognosis of less than 12 months. * Having any planned changes to mood-altering medications at the time of enrollment for the next 12 weeks.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Irreversible age-related vision loss are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • St. Joseph's Hospital, Ivey Eye Institute

    London, Ontario, N6G0H8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.